Epicardial ablation may not be necessary in all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and frequent ventricular tachycardia

We read with great interest the recent manuscript of Berruezo and colleagues who reported the results of a prospective multicentre study on ‘safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy’.1 With an aggressive approach of first-line combined endo- and epicardial ventricular tachycardia (VT) ablation in 41 patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) the authors observed recurrences of VT in 11 patients (26.8%) after a mean follow-up of 32.2  + 21.8 months. Two patients (5%) suffered from procedure-related complications due to epicardial access, including one death.1 Other researchers sought for alternative ablation strategies.
Source: Europace - Category: Cardiology Source Type: research